| [1] |
Nolan E, Lindeman GJ, Visvader JE, et al. Deciphering breast cancer: from biology to the clinic[J]. Cell, 2023, 186(8):1708-1728. DOI:10.1016/j.cell.2023.01.040.
pmid: 36931265
|
| [2] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI:10.3322/caac.21660.
|
| [3] |
Tray N, Adams S, Esteva FJ. Antibody-drug conjugates in triple negative breast cancer[J]. Future Oncol, 2018, 14(25): 2651-2661. DOI:10.2217/fon-2018-0131.
pmid: 30175620
|
| [4] |
吕玉珠, 毛大华. 精准医学时代背景下三阴性乳腺癌治疗进展[J]. 医学综述, 2021, 27(16): 3199-3203. DOI:10.3969/j.issn.1006-2084.2021.16.015.
|
| [5] |
中国抗癌协会肿瘤药物临床研究专业委员会, 国家抗肿瘤药物临床应用监测专家委员会, 国家肿瘤质控中心乳腺癌专家委员会, 等. 抗体药物偶联物治疗恶性肿瘤临床应用专家共识(2020版)[J]. 中国医学前沿杂志(电子版), 2021, 13(1): 1-15. DOI:10.12037/YXQY.2021.01-01.
|
| [6] |
Fenn KM, Kalinsky K. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors[J]. Drugs Today (Barc), 2019, 55(9): 575-585. DOI:10.1358/dot.2019.55.9.3039669.
|
| [7] |
Khongorzul P, Ling CJ, Khan FU, et al. Antibody-drug conjugates: a comprehensive review[J]. Mol Cancer Res, 2020, 18(1): 3-19. DOI:10.1158/1541-7786.MCR-19-0582.
pmid: 31659006
|
| [8] |
Starodub AN, Ocean AJ, Shah MA, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors[J]. Clin Cancer Res, 2015, 21(17): 3870-3878. DOI:10.1158/1078-0432.CCR-14-3321.
pmid: 25944802
|
| [9] |
Goldenberg DM, Cardillo TM, Govindan SV, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)[J]. Oncotarget, 2015, 6(26): 22496-22512. DOI:10.18632/oncotarget.4318.
pmid: 26101915
|
| [10] |
Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase Ⅰ/Ⅱ IMMU-132-01 basket trial[J]. Ann Oncol, 2021, 32(6): 746-756. DOI:10.1016/j.annonc.2021.03.005.
pmid: 33741442
|
| [11] |
Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J]. N Engl J Med, 2019, 380(8): 741-751. DOI:10.1056/NEJMoa18 14213.
|
| [12] |
Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J]. N Engl J Med, 2021, 384(16): 1529-1541. DOI:10.1056/NEJMoa2028485.
|
| [13] |
Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: a phase Ⅱ open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors[J]. J Clin Oncol, 2021, 39(22): 2474-2485. DOI:10.1200/JCO.20.03489.
|
